The objective of this study was to assess bioequivalence of a potential generic 600 mb
oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg
oxcarbazepine tablet, Trileptal, following a single 600 mg dose, administered with food.
- No clinically significant abnormal finding on the physical examination, medical
history, or clinical laboratory results at screening.
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with any known enzyme altering drugs.
- History of allergic or adverse response to oxcarbazepine or any other comparable or